Key Points
- Director William Phd Link sold 12,500 shares of Tarsus Pharmaceuticals on June 15 at an average price of $62.12, for total proceeds of $776,500. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Link still owned 106,786 shares valued at about $6.63 million, representing a 10.48% reduction in his position.
- Tarsus recently beat quarterly earnings and revenue estimates, while Wall Street’s view remains Moderate Buy with a consensus price target of $90.67. Institutional ownership is also high, with hedge funds and other investors holding about 90% of the stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) Director Katherine Goodrich sold 2,954 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the sale, the director directly owned 2,233 shares of the company's stock, valued at approximately $138,624.64. The trade was a 56.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tarsus Pharmaceuticals Trading Up 2.9%
TARS opened at $62.55 on Thursday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The firm has a market capitalization of $2.69 billion, a PE ratio of -54.87 and a beta of 0.49. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The company's 50-day moving average is $63.47 and its 200 day moving average is $69.54.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of hedge funds have recently modified their holdings of TARS. Rockefeller Capital Management L.P. lifted its stake in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after buying an additional 291 shares during the period. State of Wisconsin Investment Board lifted its position in shares of Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company's stock valued at $2,613,000 after buying an additional 332 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company's stock worth $2,229,000 after acquiring an additional 339 shares during the period. Finally, Valeo Financial Advisors LLC increased its holdings in Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company's stock worth $321,000 after acquiring an additional 392 shares during the last quarter. Institutional investors own 90.01% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. Zacks Research cut shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 25th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Monday, March 16th. Wall Street Zen raised Tarsus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Guggenheim raised their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $90.67.
View Our Latest Stock Analysis on TARS
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
